XML 85 R74.htm IDEA: XBRL DOCUMENT v3.25.3
Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment - Footnotes (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended
Jul. 31, 2025
Sep. 28, 2025
Sep. 29, 2024
Jun. 29, 2025
Sep. 28, 2025
Sep. 29, 2024
Segment Reporting Information [Line Items]            
Income from continuing operations before provision/(benefit) for taxes on income [1]   $ 3,334 $ 4,715   $ 9,162 $ 8,033
Acquired in-process research and development expenses   1,390 13   1,401 20
Restructuring charges/(credits) and implementation costs and additional depreciation-asset restructuring   423 398   1,150 1,930
Certain legal matters, net [2]   191 45   755 422
Certain asset impairments [3]   260 0   577 349
Charge related to expected sale of facilities     420     420
3SBio [Member] | In-Licensing Agreement Option [Member]            
Segment Reporting Information [Line Items]            
Acquired in-process research and development expenses $ 1,350 1,350     1,350  
ViiV [Member]            
Segment Reporting Information [Line Items]            
Dividend income     (48)   (184) (183)
Biopharma [Member]            
Segment Reporting Information [Line Items]            
Income from continuing operations before provision/(benefit) for taxes on income   8,469 8,269   22,429 21,707
Acquired in-process research and development expenses   40 13   51 20
Biopharma [Member] | ViiV [Member]            
Segment Reporting Information [Line Items]            
Dividend income   (72)        
Paxlovid [Member]            
Segment Reporting Information [Line Items]            
Favorable adjustment for government emergency use authorization inventory returned to the company during the period           771
Paxlovid [Member] | Biopharma [Member]            
Segment Reporting Information [Line Items]            
Favorable adjustment for government emergency use authorization inventory returned to the company during the period           771
Other Business Activities [Member]            
Segment Reporting Information [Line Items]            
Income from continuing operations before provision/(benefit) for taxes on income [1],[4]   (3,084) (1,477)   (6,230) (5,388)
Other Business Activities [Member] | Reclassification Other [Member]            
Segment Reporting Information [Line Items]            
Income from continuing operations before provision/(benefit) for taxes on income     50 $ 74   132
Reconciling Items [Member] | Certain Significant Items [Member]            
Segment Reporting Information [Line Items]            
Income from continuing operations before provision/(benefit) for taxes on income [1],[5]   $ (634) $ (299)   (2,578) (2,768)
Restructuring charges/(credits) and implementation costs and additional depreciation-asset restructuring         $ 1,000 $ 1,500
[1] Income from continuing operations before provision/(benefit) for taxes on income. Effective in the third quarter of 2025, certain costs for corporate affairs, which were previously reported in the operating results of corporate enabling functions, are reported in the operating results of our Biopharma reportable segment. In connection with this reporting change, we reclassified costs of approximately $74 million in the first six months of 2025, $50 million in the third quarter of 2024 and $132 million in the first nine months of 2024 from Other business activities to Biopharma to conform to the current period presentation.
[2] The third quarter of 2025 primarily includes certain product liability expenses. The first nine months of 2025 primarily include certain product liability and other legal expenses. The third quarter and first nine months of 2024 primarily included certain product liability expenses related to products discontinued and/or divested by Pfizer.
[3] The third quarter and first nine months of 2025 include an intangible asset impairment charge associated with our Biopharma segment of $260 million related to IPR&D associated with a Phase 3 study for inclacumab for the treatment of SCD, which reflects unfavorable clinical trial results. The first nine months of 2025 also include an intangible asset impairment charge of $210 million associated with our Biopharma segment for KRAS G12D, a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner. The first nine months of 2024 included a $240 million intangible asset impairment charge, associated with our Biopharma segment that represented IPR&D related to a Phase 3 study for the treatment of DMD, which reflected unfavorable clinical trial results.
[4] Other business activities include revenues and costs associated with PC1 and Pfizer Ignite as well as costs that we do not allocate to our operating segments, per above. Earnings in the third quarter and the first nine months of 2025 reflect a charge for $1.35 billion recorded in Acquired in-process research and development expenses related to an in-licensing agreement with 3SBio. See Note 2B.
[5] Earnings in the first nine months of 2025 include, among other items, restructuring charges/(credits), inventory write-offs, implementation costs and additional depreciation—asset restructuring of $1.0 billion (primarily recorded in Restructuring charges and certain acquisition-related costs), charges for certain legal matters of $755 million and certain asset impairments of $577 million, both recorded in Other (income)/deductions––net. Earnings in the third quarter and first nine months of 2024 included, among other items, a charge in Other (income)/deductions––net of $420 million related to the expected sale of one of our facilities resulting from the discontinuation of our DMD program. Earnings in the first nine months of 2024 also included restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $1.5 billion (primarily recorded in Restructuring charges and certain acquisition-related costs). See Notes 3 and 4.